Home » Newsletters » BioWorld Science

BioWorld Science

April 24, 2015

View Archived Issues

Adapt Pharma successfully completes pharmacokinetic study of intranasal naloxone

VolitionRx and Hvidovre Hospital initiate trial to identify NuQ biomarkers for colorectal polyps

Biohaven advancing BHV-0223 toward phase I trial

Enrollment open in phase II study of GI-6301 for chordoma

European CANCER-ID consortium formed to validate blood biomarkers of cancer

Shanghai De Novo Pharmatech characterizes AML candidate SC-110237

Clinical data reported for antibody-drug conjugate SGN-CD33A

ThromboGenics starts developing Jetrea for retinal vein occlusion

Janssen seeks Japanese approval of Risperdal for irritability in children with autistic disorder

Karus Therapeutics presents PI3Kbeta/delta inhibitors

U.S. orphan drug designation awarded to Dicerna's DCR-PH1 for primary hyperoxaluria type 1

Celgene and MedImmune collaborate to develop MEDI-4736 for hematologic malignancies

Bayer patents FXIa inhibitors

Bayer seeks Japanese approval for radium-223 dichloride

Janssen Pharmaceutica discloses NIK inhibitors

Cortendo reports development of novel cytochrome P450 inhibitors

Korean researchers present HRP-3 inhibitors

Roche divulges new tau-imaging compounds

FDA approves label update to Pomalyst

Aerie reports results from first registrational study of Rhopressa

FDA grants priority review to idarucizumab BLA

World Malaria Day: unveiling parasite resistance mechanisms

Actavis launches Avycaz in U.S.

AstraZeneca and Innate Pharma collaborate on development of IPH-2201

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...